LAUSR

lines: hematopoietic growth factors, Version 2. 2020, www.NCCN.org (accessed 26 June 2020). 3. Thompson CA, Scheneider BJ, Brahmer J, et al. NCCN guidelines: management of immunotherapy-related toxicities, Version 1. 2020, www. NCCN.org (accessed 26 June 2020). 4. Liang W, Guan W, Chen R, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol 2020; 21: 335–337. 5. Howlader NNA, Krapcho M, Miller D, et al. (eds). SEER cancer statistics review, 1975–2017. Bethesda, MD: National Cancer Institute, 2020. 6. Medscape drug interaction checker, https://reference.med scape.com/druginteractionchecker (2020, accessed 21 April 2020). 7. Drug interactions checker, https://www.drugs.com/drug_ interactions.html (2020, accessed 21 April 2020). 8. LexicompR drug interactions, https://www.uptodate. com/druginteractions/?source=responsive_home#didruglist (2020, accessed 21 April 2020). 9. McDonnell AM and Dang CH. Basic review of the cytochrome p450 system. J Adv Pract Oncol 2013; 4: 263–268. 10. Yang K. What do we know about remdesivir drug interactions? Clin Transl Sci. Epub ahead of print 14 May 2020. DOI: 10.1111/cts.12815. 11. Zhao Y, Harmatz JS, Epstein CR, et al. Favipiravir inhibits acetaminophen sulfate formation but minimally affects systemic pharmacokinetics of acetaminophen. Br J Clin Pharmacol 2015; 80: 1076–1085. 12. Obach RS, Huynh P, Allen MC, et al. Human liver aldehyde oxidase: inhibition by 239 drugs. J Clin Pharmacol 2004; 44: 7–19. 13. Du YX and Chen XP. Favipiravir: pharmacokinetics and concerns about clinical trials for 2019-nCoV infection. Clin Pharmacol Ther Epub ahead of print 5 April 2020. DOI: 10.1002/cpt.1844. 14. Kochi AN, Tagliari AP, Forleo GB, et al. Cardiac and arrhythmic complications in patients with COVID-19. J Cardiovasc Electrophysiol 2020; 31: 1003–1008. 15. Hu LY, Mi WL, Wu GC, et al. Prevention and treatment for chemotherapy-induced peripheral neuropathy: therapies based on CIPN mechanisms. Curr Neuropharmacol 2019; 17: 184–196. 16. Short-term recommendations for non-small cell lung cancer management during the COVID-19 pandemic, https://www.nccn.org/covid-19/pdf/COVID_NSCLC.pdf (2020 accessed 21 April 2020).